Clinical Trials (Phase I)
Filter News
Found 12,990 articles
-
St. Jude Children’s Research Hospital published data from its Phase I/II clinical trial of its gene therapy for SXCID or SCID-X1, also dubbed “bubble boy disease.” The research was published in the New England Journal of Medicine.
-
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
-
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD
4/18/2019
A First-in-Class Ophthalmological Recombinant Fully Human Bi-specific Fusion Protein Targeting VEGF and Complement Proteins
-
Vaxiion Therapeutics Initiates Phase 1 Clinical Trial of VAX014 for the Treatment of Non-Muscle Invasive Bladder Cancer in the United States
4/18/2019
VAX014 is a first-in-class recombinant bacterial minicell-based oncolytic immunotherapy that is engineered to selectively target a pair of NMIBC-associated cell-surface integrin heterodimers.
-
Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
4/18/2019
Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced the first healthy volunteer has been dosed in a Phase 1 clinical trial of the company's lead drug candidate IDL-2965.
-
Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Corners...
4/17/2019
Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually. -
The first clinical trials using CRISPR technology are expected to get underway in the United States, even as echoes of a scandal involving the use of CRISPR on embryos in China are still being felt across the globe.
-
Cool Science News! We Want to Know
4/17/2019
The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them. -
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a lo...
-
Collaborative Medicinal Development LLC wins AU$1 million grant award from FightMND
4/17/2019
In 2016, FightMND helped to support the phase 1 clinical trial of CuATSM where it was given to MND patients as a therapeutic for the first tim
-
Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001
4/17/2019
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first frontotemporal dementia (FTD) patient in the Phase 1b portion of the INFRONT clinical study of AL001 after successful completion of the healthy volunteer single ascending dose escalation portion of the study.
-
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
4/17/2019
United BioPharma's novel antibody suppresses HIV without eliciting resistance
-
Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
4/16/2019
Vaxart, Inc. announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial.
-
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
4/16/2019
Research Findings Accepted for Publication in Journal of Clinical Psychopharmacology
-
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
4/15/2019
Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2
-
CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors
4/15/2019
CStone Pharmaceuticals announced that the National Medical Products Administration recently approved the initiation of a Phase I/II clinical trial in China evaluating avapritinib, a drug candidate discovered by the company's partner Blueprint Medicines, in patients with unresectable or metastatic gastrointestinal stromal tumors.
-
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
-
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
-
Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial
4/11/2019
Moleculin Biotech, Inc. announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors.
-
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator
4/11/2019
Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced the positive results of AUT00206 in a Phase Ib “ketamine challenge” study in healthy volunteers.